STOCK TITAN

Syndax Pharmaceuticals Inc - SNDX STOCK NEWS

Welcome to our dedicated news page for Syndax Pharmaceuticals (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syndax Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syndax Pharmaceuticals's position in the market.

Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) CEO to participate in fireside chat at Stifel 2024 Virtual Targeted Oncology Forum. The event will be held on April 17, 2024, at 11:00 a.m. ET. Investors can access the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) presents positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory acute leukemia at the ASPHO Conference. The data highlights impressive activity and consistency with the adult population, showcasing a complete remission rate of 23% and an overall response rate of 46%. The safety profile of revumenib remains favorable, with no treatment-related discontinuations or dose reductions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) grants inducement awards to new employees, offering up to 164,200 shares of common stock under the 2023 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals completes enrollment in pivotal trial for revumenib in mutant nucleophosmin acute myeloid leukemia, with topline data expected in 4Q24 potentially supporting sNDA filing in 1H25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) receives Priority Review from the FDA for revumenib NDA, targeting adult and pediatric relapsed or refractory KMT2Ar acute leukemia. PDUFA action date set for September 26, 2024, under the RTOR program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals appoints Steven Closter as Chief Commercial Officer, bringing over 30 years of experience to lead commercial strategy. Company aims for two potential first- and best-in-class product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
management
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) grants inducement awards to new employees, offering stock options to purchase up to 42,800 shares of common stock. The options will vest over four years, with a gradual monthly vesting schedule, subject to continued employment with Syndax.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary
Incyte's axatilimab receives Priority Review acceptance for chronic GVHD treatment after positive AGAVE-201 trial results, showing promising efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals reports financial results and pipeline progress for 2023, highlighting significant milestones achieved. Key updates include BLA filing for axatilimab in chronic GVHD, NDA submission for revumenib in R/R KMT2Ar acute leukemia, and ongoing trials for both drugs. The company maintains a strong cash position expected to fund operations through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) to participate in investor conferences to discuss cancer therapies. Management team to join fireside chats and panel discussions at TD Cowen's and Barclays Global Healthcare Conferences in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
conferences
Syndax Pharmaceuticals Inc

Nasdaq:SNDX

SNDX Rankings

SNDX Stock Data

1.85B
84.63M
0.82%
106.63%
11.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About SNDX

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.